Trial Profile
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist (UAB Core Center for Basic Skeletal Research).
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms CMBD
- 19 May 2017 Status changed from completed to discontinued.
- 23 Dec 2016 Status changed from recruiting to completed.
- 31 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.